IL17A and acute respiratory distress syndrome: Heightened expression of IL-17 correlates with severe COVID-19 disease35, while neutralising IL-17 has been suggested as a possible therapy to treat acute respiratory distress syndrome in SARS-CoV-2-infected individuals36.